Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen

Acelyrin's 2024 comeback is picking up speed, as the biotech presents proof-of-concept data on a thyroid eye disease (TED) treatment just over a week after two other positive trial updates.